Clinical trial registry record

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 17, 2016.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT01414153
Last registry update
October 17, 2016
Status
Completed
Phase
Phase 2
Sponsor
Lpath, Inc.
Enrollment
158
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
158
Population
ALL · 50 Years
Duration
2012-08-01 to 2015-06-01
Intervention
4.0 mg iSONEP; 0.5 mg iSONEP; 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; sham injection
Comparator
Lucentis or Avastin or Eylea
Outcomes measured
Mean Change in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) — Baseline to…; Mean Change in Central Subfield Retinal Thickness — Baseline to Day 120; Mean Change in CNV Lesion Area as Determined by Fluorescein Angiography (FA). — Baseline to Day 120; Proportion of Subjects Gaining Greater Than or Equal to 0, 5, 10 and 15 Letters on the ETDRS Chart. — Baseline to Day 1…; Proportion of Subjects Losing 3 Lines or More in ETDRS BCVA. — Baseline to Day 120; Proportion of Subjects With ETDRS BCVA of 20/40 or Better. — Baseline to Day 120; Proportion of Subjects With Adverse Events. — Baseline to Day 120
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON